A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
Suresh S. Ramalingam,Glenwood D. Goss,Rafael Rosell,G. Schmid-Bindert,Bojan Zaric,Z. Andric,Igor Bondarenko,Dmitry Komov,Timur Ceric,Fadlo R. Khuri,Miroslav Samarzija,Enriqueta Felip,Tudor-Eliade Ciuleanu,Vera Hirsh,T. Wehler,James Spicer,Ravi Salgia,Geoffrey I. Shapiro,E. Sheldon,Florentina Teofilovici,V. Vukovic,Dean A. Fennell +21 more
TLDR
Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile and significant prolongation of PFS and OS was observed in patients >6 months from diagnosis of advanced disease, a subgroup chosen as the target population for the phase III study.About:
This article is published in Annals of Oncology.The article was published on 2015-05-21 and is currently open access. It has received 98 citations till now. The article focuses on the topics: Docetaxel & Population.read more
Citations
More filters
Journal ArticleDOI
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai,Craig M. Crews +1 more
TL;DR: Induced protein degradation has the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.
Journal ArticleDOI
Targeting Oncogenic Mutant p53 for Cancer Therapy.
Alejandro Parrales,Tomoo Iwakuma +1 more
TL;DR: This review article comprehensively discusses the current strategies targeting oncogenic mutant p53 in cancers, with special focus on compounds that restore wild-type p53 transcriptional activity of Mutant p53 and those reducing mutants p53 levels.
Journal ArticleDOI
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Marta Roman,Iosune Baraibar,Inés López,Ernest Nadal,Christian Rolfo,Silvestre Vicent,Ignacio Gil-Bazo +6 more
TL;DR: The aim of this review is to update the current knowledge about KRAS-mutated lung adenocarcinoma, including a historical overview, the biology of the molecular pathways involved, the clinical relevance of KRAS mutations as a prognostic and predictive marker and the potential therapeutic approaches for a personalized treatment ofKRAS-Mutated NSCLC patients.
Journal ArticleDOI
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
TL;DR: This review summarizes the recent advances in the studies on mutp53 protein accumulation and gain-of-function and targeted therapies for Mutp53 in human cancer.
Journal ArticleDOI
Cancer Metabolism: Current Understanding and Therapies
TL;DR: There are numerous affected oncogenes and metabolic pathways common in cancer and how they contribute to cancer pathogenesis and malignancy and the current targeted therapies that have arisen from this research.
References
More filters
Journal ArticleDOI
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
TL;DR: The results suggest the need to modify the stage IV category in NSCLC and suggest that although several factors were independent variables in the Cox models, three important prognostic subgroups were easily defined through RPA.
Journal ArticleDOI
HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Alvaro Marín-Hernández,Juan Carlos Gallardo-Pérez,Stephen John Ralph,Sara Rodríguez-Enríquez,Rafael Moreno-Sánchez +4 more
TL;DR: It is concluded that targeting the HIF1alpha-induced glucose transporter and hexokinase, important to glycolytic flux control, might provide better therapeutic targets for inhibiting tumor growth and progression than targeting HIF-1alpha itself.
Journal ArticleDOI
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis
M I Koukourakis,Alexandra Giatromanolaki,Efthimios Sivridis,Georgios Bougioukas,Vassilios Didilis,K C Gatter,Al Harris +6 more
TL;DR: It is concluded that overexpression of LDH-5 is a common event in non-small-cell lung cancer, can be easily assessed in paraffin-embedded material and provides important prognostic information, particularly when combined with other endogenous markers of hypoxia and acidity.
Journal ArticleDOI
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Eloisi Caldas-Lopes,Leandro Cerchietti,James H. Ahn,Cristina C. Clement,Ana I. Robles,Anna Rodina,Kamalika Moulick,Tony Taldone,Alexander Gozman,Yunke Guo,Nian Wu,Elisa de Stanchina,Julie D. White,Steven S. Gross,Yuliang Ma,Lyuba Varticovski,Ari Melnick,Gabriela Chiosis +17 more
TL;DR: The results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp 90 inhibitor PU-H71 for clinical trials involving patients with TNBC.
Journal Article
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
TL;DR: It is suggested that Hsp90 inhibitors can effectively suppress Akt activity in animal models of human cancer at nontoxic doses, thus sensitizing tumor cells to proapoptotic stimuli.
Related Papers (5)
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
Lecia V. Sequist,Scott N. Gettinger,Neil Senzer,Renato G. Martins,Pasi A. Jänne,Rogerio Lilenbaum,Jhanelle E. Gray,A. John Iafrate,Ryohei Katayama,Nafeeza Hafeez,Jennifer Sweeney,John R. Walker,Christian C. Fritz,Robert W. Ross,David Grayzel,Jeffrey A. Engelman,Darrell R. Borger,Guillermo Paez,Ronald B. Natale +18 more